New York, November 04, 2024 - PRISM MarketView - Corbus Pharmaceuticals (NASDAQ: CRBP) recently presented pre-clinical data on its investigational obesity treatment, CRB-913, at Obesity Week 2024. CRB-913, a CB1 inverse agonist with highly restricted peripheral action, demonstrated a significant impact on weight loss in diet-induced obesity (DIO) mice.
Key findings included:
- Brain Levels and Safety Profile: CRB-913 exhibited brain levels 15 times lower than monlunabant, suggesting lower central nervous system exposure.
- Dose-Response Weight Loss: In DIO mice, CRB-913 achieved up to 38% weight loss over a 28-day dosing period, with doses ranging from 5 to 80 mg/kg/day.
- Combination with Semaglutide: Transitioning mice from semaglutide to CRB-913 maintained and furthered weight loss, showing a doubling in fat loss compared to semaglutide alone, highlighting potential use as a follow-up maintenance treatment after incretin-based therapy.
Corbus plans to initiate a Phase 1 clinical trial for CRB-913 in early 2025.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities